Cytokinetics analyst coverage

WebApr 5, 2024 · Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. INVESTORS & … WebFintel reports that on April 13, 2024, Baird initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Outperform recommendation. Analyst Price Forecast Suggests 80.40% Upside As of April 6 ...

Cytokinetics Incorporated (CYTK) Stock Price, News ... - TheStreet

WebNov 3, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. Web1 day ago · Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd … greeting at galentines day brunch https://veresnet.org

Cytokinetics Incorporated (CYTK) Stock Price, News ... - TheStreet

WebMar 31, 2024 · Analyst Coverage; Investor FAQ; IR Contacts; Corporate Governance; Information Request; Email Alerts WebShare This: Share 2024 – Summer Analyst Internship – Financial Institutions Coverage (FIC) on Facebook Share 2024 – Summer Analyst Internship – Financial Institutions ... Financial Institutions Coverage (FIC) manages relationships with the bank’s largest institutional clients across key sectors: banks, hedge funds, asset managers ... WebCytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. Stock Information Press Releases foch de chocolate

Broker Revenue Forecasts For Cytokinetics, Incorporated (NASDAQ:CYTK ...

Category:Analysts Have Conflicting Sentiments on These …

Tags:Cytokinetics analyst coverage

Cytokinetics analyst coverage

Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv

WebApr 9, 2024 · Truist Financial initiated coverage on shares of Cytokinetics in a research note on Tuesday, December 20th. They issued a “buy” rating and a $60.00 target price for the company. Bank of America...

Cytokinetics analyst coverage

Did you know?

Web1 day ago · Similarly, MAC has 32.06% upside from the recent share price of $9.92 if the average analyst target price of $13.10/share is reached, and analysts on average are expecting HR to reach a target ... WebCYTK Stock 12 Months Forecast. $58.50. (66.24% Upside) Based on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $58.50 with a high forecast of $80.00 and a low forecast of $42.00. The average price target represents a 66.24% change from the last price of $35.19.

WebApr 6, 2024 · Analyst Price Forecast Suggests 12.99% Upside As of April 6, 2024, the average one-year price target for Broadcom is $696.81. The forecasts range from a low of $589.84 to a high of $787.50. WebFor more in-depth coverage of Tesla Motors, ... Analyst Price Forecast Suggests 12.52% Upside. As of April 6, 2024, the average one-year price target for Tesla Motors is $203.14. The forecasts ...

WebOur Corporate Responsibility Framework. Keep Patients at the Center of our Work. Continue to embed patient centricity across all stages of our business. Maintain strong … WebApr 10, 2024 · Trevor Immelman faced the tall task of being named CBS Sports’ lead golf analyst in January, replacing Nick Faldo in the 18th tower, but he soared into this weekend’s coverage of the Masters.

WebFeb 27, 2024 · Cytokinetics, Incorporated (NASDAQ:CYTK - Get Rating) has earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports.One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have given a buy …

WebMay 24, 2024 · Below is a summary of how these 4 analysts rated Cytokinetics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … foch cleanersWebApr 5, 2024 · According to analysts' consensus price target of $56.21, Cytokinetics has a forecasted upside of 60.7% from its current price of $34.99. Amount of Analyst … foch daycareWebJan 7, 2024 · Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten; Royalty Pharma Purchases Royalties on Future Sales of Aficamten; Cytokinetics to Host Conference Call and Webcast Today at 8:30 a.m. ET; NEW YORK, NY and SOUTH SAN FRANCISCO, … fochea 3 in 1WebApr 12, 2024 · Wall Street Analyst Weigh In. Several brokerages recently weighed in on CYTK. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a ... fochea blender assemblyWebPer-Share Earnings, Actuals & Estimates Cytokinetics Inc. Quarterly Annual Actual Analyst Range Consensus 0.50 0.00 -0.50 -1.00 -1.50 CYTK will report Q1 earnings on … fochea 3 in 1 blenderWebMar 31, 2024 · March 31, 2024 Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis. March 27, 2024 Cytokinetics Releases Inaugural Corporate Responsibility Report. March … greeting avery cardsWebAnalyst Coverage; Investor FAQ; IR/Media Contacts; Corporate Governance; Information Request; Email Alerts fochea blender bottle